Breast Cancer, Breast Neoplasms, Breast Tumors, Cancer, Locally Recurrent and Metastatic Breast Cancer, Metastases, Metastatic Cancer, Oncology, Solid Tumors, Tumors
Conditions
Keywords
AMG 386, Paclitaxel, Trastuzumab, Capecitabine, Lapatinib, HER2-positive, metastatic breast cancer, locally recurrent breast cancer, Taxol, Herceptin, Xeloda, Tykerb, anti-angiogenic therapy
Brief summary
The purpose of this study is to determine if AMG 386 in combination with either paclitaxel and trastuzumab or capecitabine and lapatinib is safe and well tolerated in subjects with HER2-positive locally recurrent or metastatic breast cancer. This is an open-label phase 1b trial and has 2 study parts. Study part 1 is a dose escalation study to determine a tolerable dose of AMG 386 in combination with paclitaxel and trastuzumab (cohort A) or with capecitabine and lapatinib (cohort B). Study part 2 is cohort expansion of the tolerable doses determined in part 1.
Interventions
DRUGAMG 386 30 mg/kg, Paclitaxel and Trastuzumab
AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
DRUGAMG 386 30 mg/kg, Capecitabine and Lapatinib
AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
DRUGAMG 386 10 mgkg, Paclitaxel and Trastuzumab
AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
DRUGAMG 386 10 mg/kg, Capecitabine and Lapatinib
AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
Sponsors
Amgen
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease not amenable to any local treatment with curative intent. * HER2-positive by FISH, CISH, or IHC 3+ * ECOG performance status 0 or 1 * Left ventricular ejection fraction greater than or equal to institutional lower limit of normal * Adequate laboratory studies (hematological, chemistries and urinalysis) * Life expectancy greater than or equal to 3 months * Cohort A only: * Trastuzumab naïve or trastuzumab in the neo-adjuvant setting * No clinically significant drop in cardiac function prior exposure to trastuzumab * No prior chemotherapy for metastatic or locally recurrent breast cancer * No prior lapatinib therapy * At least 3 weeks from enrollment since prior chemotherapeutic agents, including taxanes, in the neoadjuvant or adjuvant setting * At least 3 months from enrollment since prior trastuzumab in the neoadjuvant or adjuvant setting * Cohort B only: * Must have failed trastuzumab in the first-line metastatic setting. Trastuzumab must be discontinued for at least 3 weeks prior to enrollment * Must have received prior chemotherapy as adjuvant therapy or for metastatic disease * Prior chemotherapy treatment must be discontinued for at least 3 weeks prior to enrollment * No prior capecitabine * No prior lapatinib
Exclusion criteria
* Inflammatory breast cancer * Central nervous system metastasis * Clinically significant cardiovascular disease * Radiation therapy ≤ 14 days prior to enrollment. * Concurrent anticoagulation therapy, excluding aspirin, anti-platelet agents, low molecular weight heparin or low dose warfarin per protocol. * Uncontrolled hypertension defined as diastolic blood pressure \> 90 mmHg OR systolic blood pressure \> 140 mmHg. * Subjects with a history of prior malignancy, except: * For Cohort B only: * Current or prior history of long QT syndrome * Baseline ECG report of QTc interval of \> 480 milliseconds * Severe chronic liver disease (Child Pugh C)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as a dose limiting toxicity in subjects treated with AMG 386 plus paclitaxel and trastuzumab or with AMG 386 plus capecitabine and lapatinib | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs | 24 months |
| To evaluate the pharmacokinetics (PK) of AMG 386, trastuzumab, and paclitaxel (cohort A) or AMG 386, lapatinib, and capecitabine (and its active metabolite, 5-FU; cohort B) when administered in combination | 24 months |
| To estimate the incidence of anti AMG 386 antibody formation | 24 months |
| To evaluate the treatment effect as measured by the following: objective response rate (ORR), duration of response (DOR), change in tumor burden and progression-free survival (PFS) | 23 months |
Countries
Belgium, France, United States
Outcome results
None listed